布地奈德治疗慢性阻塞性肺疾病急性加重临床疗效观察

The Clinical Effect of Budesonide on COPD of Acute Exacerbation Stage

目的观察糖皮质激素布地奈德治疗慢性阻塞性肺疾病(COPD)急性加重患者的临床疗效。方法符合纳入标准的56例患者随机分成布地奈德治疗组和甲泼尼龙治疗组,观察两组治疗前后血气分析、肺功能指标、呼吸困难分级及临床有效率。结果两组治疗前后血气动脉氧分压、动脉二氧化碳分压、肺功能指标及呼吸困难分级均有不同程度的改善(P<0.05),治疗后两组血气指标、肺功能指标、呼吸困难分级和临床有效率相比差异无统计学意义(P>0.05)。结论糖皮质激素布地奈德雾化吸入对慢性阻塞性肺疾病急性加重有明显的治疗作用,并延缓肺功能的下降。

Objective To observe the clinical effect of budesonide in treatment of patients with chronic obstructive pulmonary disease （COPD） of acute exacerbation stage. Methods A randomized single-blinded study was performed. The Patients in standard observed were randomly divided into two groups：the patient in treatment with budesonide group and the patient in treatment with methylprednisolone group. The indexes were blood-gas analyses, pulmonary function, dyspnea grading and clinical effective rate of two groups. Results The indexes of PO2 , PCO2 , pulmonary function and dyspnea grading were improved after treatment of the two groups （ P 〈 0.05 ）, the indexes of PO2, PCO2, pulmonary function and dyspnea grading and the effective rates in the treatment with budesonide group were not significantly different with the treatment with methylprednisolone group （ P 〉 0.05 ）. Conclusion The results of the study indicated budesonide aerosol inhalation has obvious therapeutic effect on the patients of COPD in acute exacerbation stage, and slows decline of pulmonary function.